Post-earnings recap
Reported
Mon, Aug 4, 2025
EPS actual
$1.44
EPS est.
$0.80
EPS surprise
+81.13%
1-day move
+3.73%
—
Est. EPS
—
Est. Rev
—
Impl. Move
—
BioMarin Pharmaceuticals reported a strong EPS figure, significantly exceeding expectations, which contributed to a 3.73% increase in stock price. The lack of revenue data and guidance may leave some investors cautious, but the positive EPS surprise indicates effective cost management or strong product performance. Overall, the market reacted favorably to the earnings news.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $1.44 | N/A | +81.13% |
| Revenue | N/A | N/A | N/A |
Management expressed satisfaction with the EPS results, highlighting their commitment to innovation. However, they did not provide specific guidance for future quarters.
We are pleased with our EPS performance this quarter.
Our focus remains on innovation and delivering value to patients.